Improved Medication Adherence: Lack of patient adherence to the medication has a major impact on treatment outcomes. In certain disease areas (such as schizophrenia and other mental illnesses) improving patient adherence is a well-recognized unmet medical need, which can substantially reduce relapses and increase overall treatment success.
Reversibility: Unlike injectable formulations which are not reversible, our delivery systems allow us to create long-acting therapeutic products (lasting for as long as one year) while maintaining full reversibility. Our implant device can be easily removed by any healthcare professional should the patient experience a drug-related AE which requires immediate treatment interruption.
Improved Safety and Efficacy: Peak plasma levels of a drug are usually associated with more AEs, whereas lack of efficacy is typically linked to drug levels that are subtherapeutic. The pharmacokinetic (PK) profile of most drugs is not smooth and often includes peaks which lead to AEs, as well as subtherapeutic troughs. Our sustained-release technologies result in a smooth PK profile where the drug level stays within the therapeutic window for several months. Maintaining the appropriate PK level allows us to achieve enhanced efficacy while using a lower dose of the drug and thus improving safety.
No Treatment Initiation Required: Several injectable products require oral supplements or complex dosing schedules during treatment initiation. Delpor’s implant device begins working immediately after implantation without the need for a complex treatment initiation dosing schedule in the beginning of therapy, or re-initiation when a dose is missed.
1-Day Washout Period: Injectable products have long washout periods which complicate the dosing schedule when switching therapies. After the explantation of Delpor’s implant device, drug plasma levels fall to zero within just one day, allowing the patient to switch to another therapy immediately if needed, and without any considerations of concomitant use of different medications.
Cost Efficiency: Cost efficiency is not just about the price of healthcare resources, but also about the usage of such resources. At a time when the United States and many other countries are trying to manage healthcare costs, most of the emphasis is placed on improving the system’s efficiency, instead of reducing its overall usage. Increasing treatment success and reducing the need for physician involvement is another key way of managing healthcare costs.
Enabling Drug Development: There are several drugs that have tremendous therapeutic potential, but face considerable delivery challenges. Examples include certain peptides that are very potent but are cleared rapidly from the human body. Our technologies can enable the sustained release of drugs for several months. Such delivery can be essential in many cases in order to allow certain agents to achieve their therapeutic potential.